Gendux To Exploit Untapped Gene Therapy Research Of Europe

Introgen Therapeutics, Inc. has created a new subsidiary, Gendux Inc., to capitalize on the largely untapped gene therapy research being conducted at scientific centers across Europe. The new company, based in London, plans to make a long-term investment in the European scientific community at numerous centers of excellence through partnerships, sponsored research agreements and product collaborations with scientific leaders in both academic and corporate institutions.

Headquartered in London, Gendux will utilize the product development and manufacturing processes, research and development infrastructure, and proven gene delivery technologies of its parent company.

"While genes are being discovered daily, few companies have the expertise and infrastructure necessary to develop and commercialize gene therapy products," said David G. Nance, president and CEO of Introgen. "From inception, Gendux will have access to Introgen's facilities and management expertise, so it can focus its resources on product development."

For more information: C. Channing Burke, Corporate Communications, Introgen Therapeutics, Inc. 301 Congress Avenue, Ste. 1850, Austin, Texas 78701. Telephone: 512-320-5010 Ext. 322. Fax 512-320-4166.